Clinical Trial 22696

• Overview

  Study Title:

  Specialty Compared to Oncology Delivered Palliative Care for Patients with Acute Myeloid Leukemia SCOPE-Leukemia

  Summary:

  This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).

  Objective:

  The primary objective is to determine whether primary PC is non-inferior to specialty PC for improving quality of life (QOL) in patients with AML

• Inclusion Criteria

  Inclusion Criteria:
  • Hospitalized patients 18 years of age or older with high-risk acute myeloid leukemia (AML) defined as:
  • Patients with new diagnosis 60 years of age or older
  • An antecedent hematologic disorder
  • Therapy related-disease
  • Relapsed or primary refractory AML
  • Receiving treatment with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen requiring prolonged hospitalization; or b) hypomethylating agents +/- additional agents or modification of this regimen on a clinical trial Caregiver Inclusion Criteria:
  • Adult 18 years or older relative or friend of a participating patient who the patient identifies as living with or has in-person contact with them at least twice per week.

• Exclusion Criteria

  Exclusion Criteria:
  • Patients with a diagnosis of acute promyelocytic leukemia (APML)
  • Patients with AML receiving supportive care alone
  • Patients with psychiatric or cognitive conditions which the treating clinicians believe prohibits informed consent or compliance with study procedures
  • Patients seen by a palliative care clinician [MD or APP] during two previous hospitalizations in the six months prior to enrollment

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.